After gains of 2.5% this morning, Novo Nordisk A/S shares are now trading at $88.21. Read below for the essential facts about this stock:
-
Novo Nordisk A/S has logged a -20.1% 52 week change, compared to 25.4% for the S&P 500
-
NVO has an average analyst rating of buy and is -26.9% away from its mean target price of $120.67 per share
-
Its trailing earnings per share (EPS) is $2.96, which brings its trailing Price to Earnings (P/E) ratio to 29.8. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $4.07 and its forward P/E ratio is 21.7
-
The company has a Price to Book (P/B) ratio of 3.26 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 0.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
NVO has reported YOY quarterly earnings growth of 22.4% and gross profit margins of 0.8%
-
The company's free cash flow for the last fiscal year was $108.91 Billion and the average free cash flow growth rate is 19.0%
-
Novo Nordisk A/S's revenues have an average growth rate of 14.7% with operating expenses growing at None%. The company's current operating margins stand at 44.2%